Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

P. Widimsky, W. Wijns, J. Fajadet, M. de Belder, J. Knot, L. Aaberge, G. Andrikopoulos, JA. Baz, A. Betriu, M. Claeys, N. Danchin, S. Djambazov, P. Erne, J. Hartikainen, K. Huber, P. Kala, M. Klinceva, SD. Kristensen, P. Ludman, JM. Ferre, B....

. 2010 ; 31 (8) : 943-957.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

AIMS: Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. METHODS AND RESULTS: The chairpersons of the national working groups/societies of interventional cardiology in European countries and selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. CONCLUSION: Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027439
003      
CZ-PrNML
005      
20170215130259.0
007      
ta
008      
120816s2010 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehp492 $2 doi
035    __
$a (PubMed)19933242
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Widimský, Petr, $d 1954- $7 jn20000402682 $u Cardiocenter, 3rd Faculty of Medicine, Charles University Prague, Czech Republic. widim@fnkv.cz
245    10
$a Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries / $c P. Widimsky, W. Wijns, J. Fajadet, M. de Belder, J. Knot, L. Aaberge, G. Andrikopoulos, JA. Baz, A. Betriu, M. Claeys, N. Danchin, S. Djambazov, P. Erne, J. Hartikainen, K. Huber, P. Kala, M. Klinceva, SD. Kristensen, P. Ludman, JM. Ferre, B. Merkely, D. Milicic, J. Morais, M. Noc, G. Opolski, M. Ostojic, D. Radovanovic, S. De Servi, U. Stenestrand, M. Studencan, M. Tubaro, Z. Vasiljevic, F. Weidinger, A. Witkowski, U. Zeymer
520    9_
$a AIMS: Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. METHODS AND RESULTS: The chairpersons of the national working groups/societies of interventional cardiology in European countries and selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. CONCLUSION: Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.
650    _2
$a balónková koronární angioplastika $x statistika a číselné údaje $7 D015906
650    _2
$a dostupnost zdravotnických služeb $7 D006297
650    _2
$a mortalita v nemocnicích $7 D017052
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a infarkt myokardu $x epidemiologie $x terapie $7 D009203
650    _2
$a reperfuze myokardu $x metody $x statistika a číselné údaje $7 D015425
650    _2
$a odhad potřeb $7 D020380
650    _2
$a charakteristiky bydlení $7 D012111
650    _2
$a časové faktory $7 D013997
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wijns, William $u Cardiovascular Research Center Aalst, OLV Hospital, Moorselbaan 164, Aalst 9300, Belgium
700    1_
$a Fajadet, Jean $u Cardiovascular Research Center Aalst, OLV Hospital, Moorselbaan 164, Aalst 9300, Belgium
700    1_
$a de Belder, Mark $u The James Cook University Hospital, Middlesbrough, UK
700    1_
$a Knot, Jiří $7 xx0210890 $u Cardiocenter, 3rd Faculty of Medicine, Charles University Prague, Czech Republic
700    1_
$a Aaberge, Lars $7 gn_A_00000069
700    1_
$a Andrikopoulos, George $7 gn_A_00006663
700    1_
$a Baz, Jose Antonio
700    1_
$a Betriu, Amadeo
700    1_
$a Claeys, Marc
700    1_
$a Danchin, Nicholas
700    1_
$a Djambazov, Slaveyko
700    1_
$a Erne, Paul
700    1_
$a Hartikainen, Juha
700    1_
$a Huber, Kurt
700    1_
$a Kala, Petr, $d 1965- $7 xx0043092
700    1_
$a Klinceva, Milka
700    1_
$a Kristensen, Steen Dalby
700    1_
$a Ludman, Peter
700    1_
$a Ferre, Josephina Mauri
700    1_
$a Merkely, Bela $u -
700    1_
$a Milicic, Davor $u -
700    1_
$a Morais, Joao $u -
700    1_
$a Noc, Marko $u -
700    1_
$a Opolski, Grzegorz $u -
700    1_
$a Ostojic, Miodrag $u -
700    1_
$a Radovanovic, Dragana $u -
700    1_
$a De Servi, Stefano $u -
700    1_
$a Stenestrand, Ulf $u -
700    1_
$a Studencan, Martin $u -
700    1_
$a Tubaro, Marco $u -
700    1_
$a Vasiljevic, Zorana $u -
700    1_
$a Weidinger, Franz $u -
700    1_
$a Witkowski, Adam $u -
700    1_
$a Zeymer, Uwe $u -
700    1_
$a , $u -
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 31, č. 8 (2010), s. 943-957
856    41
$u https://pubmed.ncbi.nlm.nih.gov/19933242 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20170215130444 $b ABA008
999    __
$a ok $b bmc $g 949481 $s 784785
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 31 $c 8 $d 943-957 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...